Interferon therapy of hematologic malignancies.
Foon
K A
KA
Department of Internal Medicine, University of Kentucky School of Medicine, Lexington 40536-0093, USA.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D019337:Hematologic Neoplasms / Q000628:therapy*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000627:therapeutic use*; D007943:Leukemia, Hairy Cell / Q000628:therapy; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000628:therapy; D008223:Lymphoma / Q000628:therapy; D051379:Mice; D009101:Multiple Myeloma / Q000628:therapy; D009196:Myeloproliferative Disorders / Q000628:therapy; D013156:Splenectomy
D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D007155:Immunologic Factors; D016898:Interferon-alpha